Ebbuselenium derivative, pharmaceutical composition and application of ebbuselenium derivative
By developing an ebuseselen derivative that can inhibit the activity of Pseudomonas aeruginosa polyphosphate kinases (PPKs), the problem of difficult inhibition of bacterial survival and pathogenicity in the prior art is solved, and the effect of reducing biofilm formation and enhancing antibiotic sensitivity is achieved.
Patent Information
- Application Number
- CN202411886579.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-12-20
- Publication Date
- 2025-03-25
- Estimated Expiration
- 2044-12-20
AI Technical Summary
The prior art is difficult to effectively inhibit the activity of polyphosphate kinases (PPKs) of Pseudomonas aeruginosa, resulting in bacteria remaining survivable and pathogenic under antibiotic pressure.
Developing an ebuse selenyl derivative can effectively inhibit PPKs activity, reduce the polyphosphate level of bacteria, reduce the formation of biofilms, reduce the motility of bacteria, reduce the production of virulence factors, and enhance the sensitivity of bacteria to antibiotics.
By inhibiting the activity of PPKs, ebuse selenyl derivatives can significantly reduce the pathogenicity of Pseudomonas aeruginosa, reduce biofilm formation and virulence factor production, enhance bacterial sensitivity to antibiotics, thereby effectively preventing and treating bacterial infections.